首页 > AI前沿 > From Benchmarks to the Bench: Preference, Correspondence and Selectivity in Bidirectional Drug-Target Screening

From Benchmarks to the Bench: Preference, Correspondence and Selectivity in Bidirectional Drug-Target Screening

arXiv机器学习 2026-11-20 00:34 14 阅读 查看原文

Identifying active molecules for known targets and potential targets for existing drugs is central to drug discovery and repurposing. Drug-target interaction (DTI) models can rank vast numbers of drug-target pairs, but limited experimental capacity restricts testing to a small number of candidates.

We compared the bidirectional recommendations of 13 released systems across 711 molecular structures of FDA-approved